Duran Ayse Ocak, Karaca Halit, Besiroglu Mehmet, Bayoglu Ibrahim Vedat, Menekse Serkan, Yapici Heves Surmeli, Yazilitas Dogan, Bahceci Aykut, Uysal Mukremin, Sevinc Alper, Hacibekiroglu Ilhan, Aksoy Asude, Tanriverdi Ozgur, Arpaci Erkan, Inanc Mevlude, Dane Faysal, Ozkan Metin
Departments of Medical Oncology, Erciyes University, Kayseri, TurkeyE-mail :
Asian Pac J Cancer Prev. 2014;15(23):10375-9. doi: 10.7314/apjcp.2014.15.23.10375.
XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC).The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC.
A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity.
Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%) , stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95%CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95%CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95%CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95%CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p<0.001).
First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.
XELOX联合贝伐单抗（XELOX-Bev）和FOLFIRI联合贝伐单抗（FOLFIRI-Bev）治疗是转移性结直肠癌（mCRC）患者的有效治疗策略。本研究旨在比较一线XELOX-Bev治疗与FOLFIRI-Bev治疗对mCRC的疗效。
共纳入409例接受化疗的mCRC患者并分为两组。第1组（n=298）接受XELOX-Bev治疗，第2组（n=111）接受FOLFIRI-Bev治疗。比较总生存期（OS）、无进展生存期（PFS）、缓解率（RR）及3-4级毒性反应。
第1组的中位随访时间为11个月，第2组为15个月。第1组和第2组分别有29例（9.7%）和2例（1.8%）患者达到完全缓解，139例（46.6%）和27例（24.5%）患者达到部分缓解，88例（29.5%）和49例（44.1%）患者病情稳定，42例（14.1%）和33例（30.0%）患者疾病进展。第1组的中位OS为25个月（范围2-57个月，95%CI：22.2-27.7），第2组为20个月（范围1-67个月，95%CI：16.8-23.1）（p=0.036）。第1组的中位PFS为9.6个月（范围2-36个月，95%CI：8.8-10.4），第2组为9个月（范围1-44个月，95%CI：7.4-10.5）（p=0.019）。第1组的客观缓解率为56.4%，第2组为26.1%（p<0.001）。
与FOLFIRI-Bev相比，一线XELOX-Bev疗效更佳，缓解率更高，可延长中位PFS/OS，且安全性更好。
